

## PATENT PROTECTION AS A CRUCIAL CATALYST FOR INNOVATION IN THE PHARMACEUTICAL SECTOR

**AUTHOR** – KUMARI VANDANA SINHA & AAKRITI SINHA

STUDENTS AT AMITY UNIVERSITY, PATNA

**BEST CITATION** – KUMARI VANDANA SINHA & AAKRITI SINHA, PATENT PROTECTION AS A CRUCIAL CATALYST FOR INNOVATION IN THE PHARMACEUTICAL SECTOR, *INDIAN JOURNAL OF LEGAL REVIEW (IJLR)*, 5 (14) OF 2025, PG. 182-196, APIS – 3920 – 0001 & ISSN – 2583-2344

### ABSTRACT

Patent protection constitutes one of the most significant legal mechanisms driving pharmaceutical innovation. It provides exclusive rights to inventors, thereby enabling the recovery of substantial research and development (R&D) investments in a sector characterized by high costs, regulatory scrutiny, and extended approval timelines. By ensuring temporary market exclusivity, patent law creates a framework that incentivizes pharmaceutical companies to engage in continuous technological advancement and drug discovery.

From a legal standpoint, patent protection embodies the delicate balance between private rights and public welfare, a principle deeply embedded in intellectual property jurisprudence. However, the same system that rewards innovation can also perpetuate monopolistic pricing and limited accessibility to life-saving medicines.

The global harmonization of patent standards through the Agreement on Trade-

Related Aspects of Intellectual Property Rights (TRIPS) has intensified debates on how far patent law should protect commercial interests without undermining the right to health, recognized under various international human rights instruments.

This paper critically examines the juridical role of patent protection as both an incentive for innovation and a potential barrier to equitable healthcare. It analyzes the interpretation of patent rights by courts, the legislative frameworks governing pharmaceutical patents across jurisdictions, and the policy tools—such as compulsory licensing, patent pools, and parallel importation—designed to mediate between exclusivity and accessibility.

Through doctrinal and comparative analysis, the paper argues that while strong patent protection remains essential for sustaining pharmaceutical progress, the legal framework must evolve toward a balanced and socially responsive model. A recalibrated approach—grounded in public interest, transparency, and global cooperation—is imperative to ensure that the legal protection of innovation simultaneously upholds the ethical imperatives of justice, equity, and public health.

**Keywords** – Patent protection; Pharmaceutical innovation; Intellectual property rights, (IPRs); Research and development (R&D); TRIPS Agreement; Market exclusivity; Access to medicines; Compulsory licensing; Right to health; Knowledge-based economy; Public health policy; Innovation incentives; Pharmaceutical patents; Intellectual property law; Global trade regulations.

## 1. Introduction

As the global economy continues to evolve into a knowledge-based ecosystem, the protection of intellectual property rights (IPRs) has emerged as a cornerstone of economic and scientific progress. Within this framework, patent law plays a particularly crucial role in promoting pharmaceutical innovation, where the creation of new drugs demands enormous investments in research, development, and regulatory compliance. By granting inventors exclusive rights for a limited duration, the patent system provides a legal mechanism that enables innovators to recoup their investments and fund future technological advancements. This system forms the foundation of modern pharmaceutical progress, fostering an environment where innovation, competition, and access to capital are intrinsically linked.

The pharmaceutical industry stands apart from other sectors due to its high-risk innovation model—marked by prolonged R&D cycles, complex clinical testing, and a high probability of failure. In such a context, patent protection functions not merely as an economic incentive but as a legal assurance of market exclusivity, essential for attracting private investment. The rationale is grounded in the belief that without sufficient legal protection, firms would lack the incentive to invest in the uncertain and capital-intensive process of drug discovery. This principle has been reinforced through various international frameworks, most notably the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), administered by the World Trade Organization (WTO), which harmonizes patent standards globally.

This paper seeks to examine the legal, economic, and policy dimensions of patent protection as a key driver of pharmaceutical innovation. It explores how patents

operate as instruments of both incentivization and regulation, shaping global drug markets and influencing access to medicines. The study further analyzes judicial interpretations of pharmaceutical patent rights, the role of TRIPS flexibilities such as compulsory licensing, and emerging trends in public-private collaboration.

Ultimately, the paper argues that while robust patent regimes remain indispensable to sustaining pharmaceutical progress, their design and enforcement must reflect a balanced, rights-based approach—one that promotes innovation while safeguarding the right to health as an integral part of international human rights law.

## 2. The role of intellectual property rights in knowledge-based economies

As the world's economies become more knowledge-based, protection of intellectual property rights (IPRs) becomes more important. IPRs are exclusive rights fostering innovation, entrepreneurship, and investment in knowledge-based assets, which ultimately contribute to economic growth by creating the prospect of a return on investment [1] and by facilitating knowledge diffusion.

Patents protect new, technology-based products and processes from being appropriated by third parties, which would dilute the ability of inventors to recoup their investments and to profit from their inventions [2]. The patent system is an incentive system; an exclusive right with economic value is granted for a limited time in exchange for disclosure of the technology that advances the scientific prior art to the benefit of society. It operates at different levels, providing an incentive to invent, disclose, and optimize exploitation efficiency as well as to innovate and diffuse, while providing a tool for governance of markets and firms in a globalized knowledge market economy [3]. Knowledge diffusion [4] is enhanced by the disclosure requirement in the patent application process, which facilitates new

collaborations, partnership and licensing arrangements. In this regard, empirical evidence suggests that patent disclosure increases licensing opportunities [5] and that licensees themselves make significant investments in research and development (R&D) [6].

Disclosure not only reveals the existence of the technology, but also enables a person sufficiently skilled in the art to use the information to make further advances [7]. In essence, the IP system is an exchange between society and inventor in which the grant of exclusive rights potentially sacrifices short-term efficiency gains in order to foster “dynamic long-term efficiency in the form of greater innovation and creativity” [8]. The Role of Intellectual Property and Patents in Driving Innovation and Economic Growth In today's increasingly knowledge-based global economy, the protection of Intellectual Property Rights (IPRs) has become paramount. IPRs are exclusive rights that serve as crucial catalysts for innovation, entrepreneurship, and investment in knowledge-based assets. By creating the prospect of a return on investment and facilitating knowledge diffusion,

IPRs significantly contribute to economic growth.

Specifically, patents offer protection for novel, technology-based products and processes, preventing unauthorized use by third parties. This protection is essential as it safeguards the inventors' ability to recoup their investments and profit from their creations. The patent system functions as an incentive mechanism: an exclusive, time-limited right with economic value is granted in exchange for the public disclosure of the technology. This disclosure advances the scientific prior art, benefiting society as a whole.

The patent system operates on multiple levels:

Incentive to Innovate: It encourages invention, disclosure, and efficient exploitation of the technology.

Market Governance: It provides a tool for managing markets and firms within a globalized knowledge economy.

Knowledge Diffusion: The mandatory disclosure in the patent application process actively enhances the spread of knowledge. This disclosure fosters new collaborations, partnerships, and licensing arrangements. Empirical evidence supports this, suggesting that patent disclosure increases licensing opportunities and prompts licensees to make substantial investments in Research and Development (R&D).

Beyond simply revealing the existence of a technology, disclosure enables experts in the field to utilize the information for further scientific and technological advancements. Fundamentally, the IP system represents an exchange between society and the inventor. Although the grant of exclusive rights may involve a short-term sacrifice of efficiency, this trade-off is made to foster “dynamic long-term efficiency in the form of greater innovation and creativity.”

3. The importance of patents for the pharmaceutical industry – empirical evidence

The growing economic importance of patents over the last decades has underscored the role of IP in contributing not only to innovation, but also to competition and trade. In particular, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which is governed by the World Trade Organization (WTO), sets minimum standards for national IP laws, including patent laws. These standards, incorporated into national patent laws according to each country's requirements, are aimed at facilitating trade among the WTO's member states.

Two caveats apply to the present discussion. First, the role of patents as a key driver for innovation, though significant for the pharmaceutical industry, cannot be generalized across all sectors. The number of patents

granted worldwide has roughly tripled from 400,000 in 1995 to 1.2 million in 2012 [9], but not all industries have been equally innovative or relied on patent protection to secure investment.

For pharmaceuticals, however, there is strong empirical evidence that patents have led to the socially desired result of higher R&D spending on developing new life-saving medicines and therapies [10]. Not only have investments increased, but drug approvals also continue to run at high levels; for example, the US Food and Drug Administration (FDA) approved 182 novel medicines between 2011 and early 2016 [11]. Today's drug discovery and innovative R&D activities take place in an environment of growing complexity, alongside the need for greater resources and incentives for investments in a scientific field with a high failure rate.

Second, patent quality meant not to encompass each and every granted patent, but only those timely granted, providing for legal certainty in the innovation ecosystem. The majority of legal [12] and economic scholars assume such quality if the patent (1) withstands a legal challenge without being invalidated, and (2) "fulfil[s] the key objectives of the patent system, i.e. to reward and incentivise innovation while enabling diffusion and further technological developments" [13], granted without any significant lag [14].

Recent WIPO data show patent filings worldwide increasing by 7–10 percent a year, with China now filing more applications than the US and Japan combined [15]. The rising patent filing trend has been observed for decades, and there is empirical evidence for a significant impact on the medical innovation ecosystem too, especially for the pharmaceutical industry [16]. Most of the value of today's medicines does not stem from their physical material, but from the continued efforts in research, testing, and innovation required to

develop them [17]. So it is not surprising that pharmaceutical and biotechnological patents have the highest indices in studies that aim at measuring both the economic and technological value of patents [18] and their originality [19]. Patent protection is a critical driver for innovation, particularly within the pharmaceutical sector, a significance highlighted by the growing economic importance of Intellectual Property (IP) in competition and trade. The WTO's TRIPS Agreement establishes minimum, nationally adaptable standards for IP and patent laws, aimed at facilitating global trade among member states.

While the role of patents is not universally generalizable across all sectors— as evidenced by the worldwide tripling of granted patents from 400,000 in 1995 to 1.2 million in 2012— it is empirically vital for the pharmaceutical industry. For this sector, strong patent protection has successfully spurred higher Research and Development (R&D) spending, leading to the development of new, life-saving medicines. This increased investment coincides with sustained high levels of drug approvals; for example, the

US FDA approved 182 novel medicines between 2011 and early 2016. Modern drug discovery is a complex, resource-intensive field with a high failure rate, making robust incentives for investment essential.

A second crucial consideration is patent quality, which refers specifically to patents that are timely granted and provide legal certainty. Legal and economic scholars generally agree that a quality patent must: 1) successfully withstand a legal challenge without being invalidated, and 2) achieve the key objectives of the patent system, which are to reward and incentivize innovation while simultaneously enabling its diffusion and further technological development.

Global trends show that patent filings are increasing by 7–10 percent annually, with WIPO data indicating that China now files more

applications than the US and Japan combined. This sustained rise has a significant impact on the medical innovation ecosystem, particularly pharmaceuticals. The value of modern medicines is largely

derived not from their physical material, but from the continuous research, testing, and innovation required for their development. Consequently, pharmaceutical and biotechnological patents consistently register the highest indices in studies measuring both the economic and technological value, as well as the originality, of patents.

#### 4. Understanding pharmaceutical research and manufacturing

Whether patent protection for pharmaceutical products and processes hinders access to innovative medicines is a long-standing and often highly politicized issue between stakeholders, though mainly in a legal and policy context. As stated above, patents promote innovation by providing an incentive to invest in R&D, while they function to structure, define and build innovation partnerships at the same time. Developing new medicines requires high investments in R&D that are essentially speculations on profitable scientific progress to the benefit of mankind. However, the failure rate is high. Unless a few patent-protected commercially-successful drugs are able to recoup investments and generate a profit, finance will dry up and the industry will fail to deliver new drugs.

Before discussing the economic and policy side of pharmaceutical patents, it would be worth having a closer look at the scientific side to see where industry and scientific progress currently stand. It may also be opportune from a pure policy perspective to raise awareness of the scientific complexity of today's R&D and manufacturing. Biologic drugs are complex molecules; they are used as very specific therapeutics that are essential to the health and well-being of patients around the world for

diseases which in most cases could not otherwise be treated.

The debate over whether pharmaceutical patent protection impedes access to innovative medicines is a persistent, often highly politicized, legal and policy issue. Patents, however, serve as a vital mechanism for promoting innovation by incentivizing the substantial R&D investments required to develop new drugs. These investments are inherently speculative, aiming for profitable scientific breakthroughs for the benefit of humanity, but face a high rate of failure. Without a few commercially successful, patent-protected drugs to recoup costs and generate profit, funding would cease, preventing the industry from delivering new treatments.

Before delving into the economic and policy aspects of pharmaceutical patents, it is useful to consider the scientific landscape to understand the current state of industry and scientific progress. From a policy standpoint, it is also important to raise awareness of the scientific complexity inherent in modern R&D and manufacturing. For example, biologic drugs are complex molecules used as highly specific therapeutics. They are essential for the health and well-being of patients globally, often treating diseases for which no other options exist.

#### 5. Understanding the market

##### 5.1. Knowledge-based capital as a prerequisite for gaining access to financing

As both discovery and manufacturing have become more complex and expensive, financing risky R&D has become more difficult, especially since the financial crisis in 2008. Investment appears economically favourable if time-limited patent protection offers the prospect of recouping the investment and generating a profit. According to a recent OECD study [20], young, innovative companies contribute 17 percent to the job market and a

disproportionate 45 percent to job creation. An important success factor is access to financial market instruments; new capital is often relatively difficult to obtain in the absence of a loan history and a traditional collateral. For young pharmaceutical companies operating in an R&D- and resource intensive environment, patents can be considered an asset and a positive managerial and technological signal to lenders and investors to provide financing [21].

Even where there is access to financing, asymmetric information, which describes cases in which the investor or lender is not completely able to receive all information for an informed decision, moral hazards, and other specific features of innovation can have the “combined effect of driving interest rates for financing innovation higher than for other types of financing” [22]. These rates can be significantly lowered for companies with a patent portfolio. Innovative companies with IP assets are able to finance projects more easily by obtaining venture capital [23], which is usually accompanied by the introduction of senior management to the company.

Investors see exclusive rights, such as patents as potential drivers of profitability and competitive advantage, even though the patented product may still be in its early stages of development and need to be further developed and tested for its safety and efficacy.

Furthermore, where there is a functioning secondary market for patents, they can serve as collateral in debt financing and can be sold separately. Policymakers in several countries are currently supporting their IP secondary market, mainly through greater transparency of IP ownership [24] and the creation of new IP market infrastructures [25]. Knowledge-based capital in the form of patents is linked to higher productivity and growth, mainly because the initial costs are not re-incurred when knowledge is used again and because knowledge generates considerable spill-over effects for other sectors [26].

Although it has been questioned whether the patent system can spur innovation and progress in countries with less relevant markets for the pharmaceutical industry [27], patents are assumed to help in gaining access to financing as a prerequisite for local R&D activities that address local needs. However, the value of knowledge-based capital depends on its use, ease of access, level of transaction costs, and extent of protection [28]. In countries without effective IP enforcement, a granted patent alone might not lead to the desired financing, growth, and higher productivity. Patent Protection as a Catalyst for Pharmaceutical Financing and Growth Financing high-risk pharmaceutical R&D has become increasingly challenging, particularly since the 2008 financial crisis, due to the growing complexity and expense of both discovery and manufacturing. Time-limited patent protection makes investment economically viable by offering the prospect of recouping costs and generating profit.

For innovative young pharmaceutical companies operating in a resource-intensive R&D environment, access to financing is a crucial success factor. Patents serve as a valuable asset and a positive managerial and technological signal to potential lenders and investors, which is especially important since new capital is often difficult to secure without a prior loan history or traditional collateral.

Even when financing is available, inherent challenges in the innovation space— such as information asymmetry, moral hazards, and other specific features— often drive interest rates for innovation financing higher than for other types of financing. However, a company's patent portfolio can significantly reduce these rates. Companies

with intellectual property (IP) assets, like patents, can more easily secure venture capital, which often brings in senior management expertise. Investors view these

exclusive rights as potential drivers of profitability and competitive advantage, even if

the patented product is still in early development and requires further testing for safety and efficacy.

Furthermore, patents can be used as collateral in debt financing and can be sold separately where a functional secondary market exists. Policy makers in various countries are actively supporting the IP secondary market, primarily by improving the transparency of IP ownership and creating new IP market infrastructures.

Knowledge-based capital, in the form of patents, is strongly linked to higher productivity and growth. This is because the initial cost of knowledge is not re-incurred upon subsequent use, and knowledge generates significant spill-over effects for other economic sectors.

While the role of the patent system in spurring innovation in countries with smaller pharmaceutical markets has been debated, patents are generally assumed to be a prerequisite for gaining access to financing. This financing, in turn, enables local R&D activities that address specific local needs. However, the true value of knowledge-based capital depends on its effective use, ease of access, low transaction costs, and the extent of its legal protection. In nations lacking effective IP enforcement, a granted patent alone may not be sufficient to deliver the desired financing, growth, and increased productivity.

## 5.2. Patents and access to medicines

As patents are exclusive rights, they do –by nature and design –result in higher prices for a limited amount of time than if the innovation could be directly copied and sold. However, policy discussions on whether patents hinder access to medicines often take place in a context in which, without those patents, the medicines in question would not have been discovered in the first place. At least for essential medicines there seems also to be little evidence that patent protection hinders access to such medicines or

treatments; only 8 percent of medicines on the Essential Medicines List of the World Health Organization are patent-protected [29].

Overall, access to medicines is determined by a variety of factors in combination rather than by patent protection alone. Access often depends on the price of a drug, which in turn is influenced by the regulatory system, distribution costs, importer and supply chain margins, and investment in physicians' and patients' outreach and education [30]; policy factors include taxation, procurement policies, and the use of TRIPS flexibilities. While the availability of these flexibilities has in general facilitated cooperation and can be useful in limited contexts, like health emergencies, their disproportionate use in some cases has resulted in higher prices and delayed availability of new medicines, both ultimately worsening access. Data show that countries with developed IP systems gain access to new medicines earlier than others [31].

However, this finding appears to apply mainly to high-income countries with attractive markets. Significant empirical evidence for the impact of patents on access in developing countries is missing. Currently available studies are mostly inconclusive and the results are not completely understood given the high level of heterogeneity between different countries [32]. For example, one study [33] found that patent regimes accelerate the entry of new treatments for HIV/AIDS in developing countries, but only in those with relatively equally distributed incomes.

Price premiums for patent-protected medicines in developing countries following implementation of the TRIPS Agreement are relatively small; implementation has mostly resulted in higher sales, and better and faster availability of medicines [35].

Contrary to the expectations of some stakeholders, India's implementation of the TRIPS Agreement has not led to high price premiums that could be considered a barrier to access. Although a model study beforehand had predicted a sharp rise [36], the price increase for patented drugs following the Indian reform was 3 -- 5.3 percent overall, 6–12 percent comparing patented drugs and drugs where the application was still pending, and only about 20 percent for patented, newly developed drugs [37]. In comparison, patented medicines in the US market cost on average three times as much as the subsequently marketed generic drug [38]. In addition, one study even suggests that it was India's obligation to comply with TRIPS that transformed several companies' business models from imitation-based to innovation-based [39].

And finally, it should be mentioned that innovative medicines are the basis for the development and later launch of lower-priced generic medicines. By fostering innovation, patents indirectly contribute to making new generic medicines available.

Moreover, generic companies in emerging economies are themselves starting to invest in R&D in order to further develop off-patent medicines adapted to local needs. Therefore, it can be concluded that patent protection does not necessarily hinder access to generic drugs, but is an enabler for the existence of generic drugs and furthermore encourages innovation by the generic industry itself. Patent protection, by its nature, grants exclusive rights that lead to temporarily higher prices compared to non-patented alternatives. However, discussions about patents obstructing access to medicines often overlook that without such protection, many of these innovations might never have been developed. Furthermore, there is limited evidence that patents significantly impede access to essential medicines, as only

8% of the drugs on the WHO Essential Medicines List are patent-protected.

Access to medicine is a complex issue influenced by multiple factors, not just patent protection. These factors include the drug's price, which is shaped by regulatory systems, distribution and supply chain costs, market margins, and investment in professional and patient education. Policy decisions, such as taxation, procurement strategies, and the use of TRIPS flexibilities, also play a role. While these flexibilities can be beneficial, particularly in emergencies, their overuse has sometimes resulted in delayed availability and increased prices for new medicines, ultimately harming access. Countries with mature intellectual property (IP) systems generally gain earlier access to new medicines.


This finding, however, seems mainly relevant to high-income countries with attractive markets. The empirical evidence on the impact of patents on access in developing countries is often inconclusive, with results difficult to interpret due to significant heterogeneity across nations. For instance, one study suggested that patent regimes accelerate the entry of new HIV/AIDS treatments in developing countries, but only in those with relatively equitable income distribution. Counterbalancing this, evidence indicates that innovative companies' investment in medical education can increase the availability of new treatments for patients in developing countries.

Following the implementation of the TRIPS Agreement, the price premiums for patent-protected medicines in developing countries have been relatively minor. The implementation generally resulted in increased sales and faster, better availability of medicines. Contrary to some predictions, India's adoption of the TRIPS Agreement

did not cause price increases severe enough to be a significant barrier to access. While a pre-reform model had forecast a sharp rise, the actual price increase for patented

drugs was modest: 3–5.3% overall, 6–12% when

Innovation and Access: Design Considerations



comparing patented drugs to those with pending applications, and about 20% for newly developed, patented drugs. This contrasts sharply with the US, where patented medicines often cost about three times more than their later-marketed generic counterparts. Intriguingly, some analysis suggests that the obligation to comply with TRIPS spurred some Indian companies to shift their business model from imitation to innovation.

Finally, innovative medicines are the prerequisite for the later development and launch of lower-priced generic versions. By fostering innovation, patents indirectly enable the eventual availability of generic medicines. Furthermore, generic companies in emerging economies are now beginning to invest in R&D to adapt off-patent medicines to local needs. Thus, patent protection should not be seen as a hindrance to generic drugs but rather as an enabler for their existence and a catalyst for innovation within the generic industry itself.

Fig. 1. Source: Taubman, A Typology of Intellectual Property Management for Public Health

for Policymakers, *Open Aids J*, 4, 2010: 4–24.

### 5.3. New strategies and models

Most pharmaceutical research is not publicly funded, nor could it all be publicly funded as a public fund could never fund amounts that the capital market can. However, high costs and risks for private investment in pharmaceutical R&D have led research to focus mainly on therapeutic areas with a relevant market for innovative medicines and therapies. This has led to the neglect of some areas by private sector R&D efforts. The World Health Organization, the industry, national authorities, NGOs and other stakeholders have recognized these market failures, especially with regard to neglected tropical diseases (NTDs), and have established several successful collaborations to address this issue, with encouraging outcomes.<sup>2</sup> Nevertheless, some stakeholders advocate a radical change of the current R&D model.

While some proposed measures have their theoretical and/or practical merits, and can complement the current privately funded R&D model, they cannot replace it.

From a pragmatic point of view, charitable R&D initiatives, state-directed R&D, and/or public-private partnerships could not sufficiently finance the development of needed innovative medicines in an efficient and sustainable way as through the current capital-market based R&D model (Fig. 1).

No alternative R&D models could replace the private pharmaceutical R&D model with its functioning patent system, without severely affecting the development of new life-saving medicines. The often discussed “de-linkage” of the price for a medicine and R&D costs remains academic as none of the suggested models could provide the continued supply of resources for research as the financial markets do.

Especially with regard to NTDs, where market incentives are not available, the further fostering of collaboration between WHO, industry, national authorities and other stakeholders –complementing rather than replacing private-sector funded research –can be expected to continue to produce encouraging results in the future. New models should therefore be seen as complementary, as add-ons to current collaborations, rather than as radical changes to the current innovation ecosystem.

The majority of pharmaceutical research is privately funded, as public funds are insufficient to match the investment capacity of the capital market. However, the high costs and risks associated with private R&D incentivize a focus on therapeutic areas with significant market potential, leading to the neglect of certain fields, such as neglected tropical diseases (NTDs).

Market failures in this regard have been acknowledged by the World Health Organization (WHO), industry, national authorities, NGOs, and other stakeholders, resulting in successful collaborations with positive outcomes, particularly for NTDs. Despite these successes, some stakeholders continue to advocate for a complete overhaul of the current R&D model.

While alternative R&D proposals, such as charitable initiatives, state-directed research, or public-private partnerships, may offer theoretical or practical benefits and can complement the existing system, they are not viable as replacements. Pragmatically, these alternatives could not provide the efficient, sustainable, and extensive financing for innovative medicines that the current capital-market-based model does.

No alternative R&D framework could adequately substitute the private pharmaceutical R&D model and its patent system without severely hindering the development of new life-saving medicines. The concept of “de-linkage” – separating a medicine’s price from its R&D costs – remains theoretical because none of the suggested models can guarantee the sustained resource supply provided by financial markets.

Therefore, for areas lacking market incentives, such as NTDs, the best path forward is to further strengthen collaborations between the WHO, industry, national authorities, and other parties.

These new models should be viewed as supplementary additions to current collaboration efforts, rather than radical changes intended to replace the existing, privately-funded research ecosystem.

6. Questions and answers related to topic ‘Patent protection as a key driver for pharmaceutical innovation’

Q1. How does the patent system function as an incentive mechanism within the pharmaceutical industry, and what legal rationale underpins this structure?

Answer:

The patent system operates as an incentive mechanism by granting inventors exclusive rights over their pharmaceutical inventions for a limited period, thereby allowing them to recoup R&D investments and generate profit before generic competition enters the market. Legally, this structure is grounded in the utilitarian theory of intellectual property, which views patents as a social

contract: inventors receive temporary monopolies in exchange for public disclosure of their inventions. This disclosure requirement facilitates knowledge diffusion, enabling further technological development and collaboration. The system, thus, embodies a balance between short-term inefficiency (monopoly pricing) and long-term societal gain (innovation and technological advancement).

Q2. To what extent has the TRIPS Agreement influenced the harmonization of pharmaceutical patent protection, and what are its implications for national sovereignty in IP policymaking?

Answer:

The TRIPS Agreement under the World Trade Organization (WTO) has been instrumental in harmonizing minimum standards for intellectual property protection, including pharmaceutical patents, across member states. While it ensures that all signatories adopt a baseline of patent protection, it simultaneously constrains domestic legislative discretion in tailoring IP laws to local public health needs. This has led to tension between international obligations and national sovereignty, especially in developing countries seeking to use TRIPS flexibilities such as compulsory licensing to ensure medicine accessibility. Gawel highlights that TRIPS has intensified debates on the balance between innovation incentives and the right to health, revealing how international economic law intersects with human rights law in the governance of pharmaceutical patents.

Q3. How can the legal framework governing patents reconcile the tension between exclusive rights and equitable access to medicines?

Answer:

The legal framework governing pharmaceutical patents must navigate a persistent tension between exclusive proprietary rights and the public's right to access essential medicines. Patents, by design, grant temporary monopolies to inventors to incentivize innovation and recover high R&D costs.

However, this exclusivity can, in practice, lead to price barriers that limit access, especially in developing economies. To reconcile this tension, patent law must be interpreted and applied in light of the doctrine of public interest and the right to health, recognized under instruments such as the International Covenant on Economic, Social and Cultural Rights (ICESCR).

Mechanisms such as compulsory licensing, parallel importation, and the use of TRIPS flexibilities serve as legal tools to mitigate inequities arising from patent monopolies. Furthermore, fostering technology transfer, voluntary licensing, and collaborative R&D models can promote innovation while ensuring that the benefits of scientific advancement are widely shared. Thus, an equitable patent regime is one that balances innovation incentives with distributive justice, ensuring that intellectual property law functions not as an obstacle but as an enabler of public health.

Q4. How do patents serve as instruments for attracting investment in pharmaceutical R&D, particularly in a post-2008 global financial environment?

Answer:

In a post-2008 financial climate characterized by reduced liquidity and heightened investment risk, patents function as critical financial assets that signal technological credibility and secure investor confidence. Explains that patents can be used as collateral, traded in secondary IP markets, or leveraged

to obtain venture capital. From a legal-economic standpoint, patents reduce information asymmetry between innovators and investors, making R&D financing more feasible. Juridically, this underscores the intersection of patent law and financial regulation, where intellectual property rights are treated as tangible economic assets contributing to knowledge-based capital. The author also notes that governments are strengthening IP transparency frameworks to enhance market efficiency, recognizing patents as essential to the capitalization of innovation.

Q5. What legal and policy considerations should guide the future evolution of the pharmaceutical patent system to ensure a balance between innovation incentives and public health imperatives?

Answer:

The future of the pharmaceutical patent system must be guided by a dual-objective framework—preserving strong incentives for research and development (R&D) while ensuring affordability and accessibility of essential medicines. From a legal standpoint, this requires the adoption of a balanced approach rooted in proportionality and public interest principles. Patent protection should remain robust enough to attract investment and foster innovation, yet flexible enough to accommodate mechanisms such as compulsory licensing, patent pools, and public-private partnerships in circumstances where public health demands broader access.

Policy reform should also focus on strengthening transparency in IP ownership, improving technology transfer mechanisms, and encouraging collaborative R&D models that bridge private innovation with public health objectives. Moreover, empirical evidence suggests that the introduction of secondary IP markets and clearer enforcement mechanisms enhances innovation financing

without necessarily hindering accessibility. The ultimate challenge for policymakers and legal systems lies in maintaining a dynamic equilibrium—where patent law continues to incentivize scientific progress while upholding the right to health as a fundamental component of human rights and international legal order.

## 7. Conclusion and outlook

This article aims to raise understanding of pharmaceutical R&D, its economic aspects from a capital-market perspective, and the role of patents as a key enabler for pharmaceutical R&D and innovation to the benefit of patients. Today's most effective and cost-intensive medicines are protein therapeutics which can only be developed with enormous investment in resources. The growing complexity of both drug discovery and manufacture for such medicines will demand a corresponding increase in the resources needed. This underlines the importance of patents as an incentive and source of growth and innovation. The technological and economic framework in which pharmaceutical R&D takes place requires a finely-tuned patent system that encourages continued scientific progress to combat current and future diseases.

While the analysis of large data sets has shown that the individual value of pharmaceutical patents was slightly declining since 2004 [40] and may continue to decline, patents remain of crucial importance to the pharmaceutical industry to attract investment, and by this, have the means to fail, learn and succeed in the future. recommendations to support creation of an innovation-friendly environment.

## The Crucial Role of Patents in Pharmaceutical Innovation

This article explores the economics of pharmaceutical Research and Development (R&D) from a capital-market perspective,

emphasizing the vital role of patents in driving innovation for the benefit of patients. Developing today's most effective— and most expensive— medicines, such as protein therapeutics, requires massive investment. The increasing complexity of both discovering and manufacturing these drugs necessitates a corresponding surge in resources. This reality underscores the essential function of patents as both an incentive for innovation and a source of growth. Consequently, the technological and economic landscape of pharmaceutical R&D demands a finely-tuned patent system to encourage continuous scientific advancement against current and future diseases.

#### Patents as a Foundation for Investment

Although analysis of large datasets suggests that the individual value of pharmaceutical patents has seen a slight decline since 2004 and may continue to do so, patents remain critically important. They are necessary for the pharmaceutical industry to attract the investment required to fund research, allowing companies the financial capacity to withstand failures, learn, and ultimately succeed in future drug development.

#### Global Impact and Policy Considerations

Patents' positive effects on innovation and access to new medicines are well-documented in high-GDP, developed economies. However, studies in low-income countries are often inconclusive and show significant differences when compared to high-income settings. While no universal Intellectual Property (IP) policy exists, a well-implemented patent system compliant with the TRIPS agreement, coupled with a robust judicial enforcement mechanism, appears beneficial for all nations. Since research has observed neither consistently positive nor negative impacts in low-income countries, many are now strengthening their IP laws and building capacity to stimulate local innovation and participate in the global movement toward knowledge-based economies. Most current studies focus

on the process of low- and middle-income countries establishing their IP systems, rather than the post-implementation effects on fostering innovation. Nevertheless, it is reasonable to assume that establishing these IP frameworks will eventually help address more localized health issues. Further empirical studies are encouraged to improve the understanding of IP systems' impact in low- and middle-income countries, which will aid in formulating concrete policy recommendations to support the creation of innovation-friendly environments.

#### References

- [1] OECD, *New Sources of Growth: Knowledge-based Capital*, p. 416: "There is a need, furthermore, to ensure that the importance of intangible assets is given sufficient recognition to secure the levels of investment required for their continued growth and economic contribution."
- [2] *Id.*, p. 8.
- [3] Ove Granstrand, presentation "Patents and Innovation for Growth in a Converging World Economy", WIPO Seminar Series on "The Economics of Intellectual Property", 5 September 2011.
- [4] OECD, *New Sources of Growth: Knowledge-based Capital*, p. 31.
- [5] Hegde/Luo, *Imperfect Information, Patent Publication, and the Market for Ideas*, p. 26.
- [6] Arora/Athreye, *Patent Incentives: Returns to Patenting and the Inducement for Research and Development*, p. 7f.
- [7] Graham et al., *High Technology Entrepreneurs and the Patent System: Results of the 2008 Berkeley Patent Survey*, 24 *Berkeley Tech. L.J.* 1255 (2009), p. 1326f.
- [8] OECD, *New Sources of Growth: Knowledge-based Capital*, p. 416f.

- [9] WIPO, World Intellectual Property Indicators 2013, p. 48, Figure A.1.2.1.
- [10] OECD, New Sources of Growth: Knowledge-based Capital, p. 431 with further references, though cross-sectorial research with highly aggregated data, such as Westmore, 2013, p. 21, is sometimes used to argue for the opposite.
- [11] Center for Drug Evaluation and Research, New Drugs at FDA: CDER's New Molecular Entities and New Therapeutic Biological Products.
- [12] Bessen/Meurer, Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk, p. 254f.; Devlin, The Misunderstood Function of Disclosure in Patent Law, p. 443f.
- [13] OECD, New Sources of Growth: Knowledge-based Capital, p. 88 with reference to Guellec/van Pottelsberghe de la Potterie, The Economics of the European Patent System: IP Policy for Innovation and Competition.
- [14] Harhoff/Wagner, The Duration of Patent Examination at the European Patent Office; Motsoeneng, South Africa tackles drug approval delays, Reuters article from 29 May 2012.
- [15] WIPO, World Intellectual Property Indicators 2015, p. 23, 37.
- [16] Levin et al., p. 824; OECD, New Sources of Growth: Knowledge-based Capital, p. 431.
- [17] OECD, New Sources of Growth: Knowledge-based Capital, p. 13.
- [18] Id., p. 91, calculations based on PATSTAT (EPO, April 2012), October 2012, indexed by industry.
- [19] OECD, New Sources of Growth: Knowledge-based Capital, p. 111f. with reference to Hall, et al., The NBER Patent Citation Data File: Lessons, Insights and Methodological Tools, defined as resulting from a large number of diverse knowledge sources.
- [20] OECD Science, Technology, and Industry Scoreboard 2013, p. 198.
- [21] OECD, New Sources of Growth: Knowledge-based Capital, p. 9.
- [22] OECD, New Sources of Growth: Knowledge-based Capital, p. 57f.
- [23] Hall/Harhoff, Recent Research on the Economics of Patents, p. 4; Hoenen, et al., Do Patents Increase Venture Capital Investments between Rounds of Financing?, p. 22f.
- [24] Harhoff, The Role of Patents and Licenses in Securing External Finance for Innovation, p. 13f.; Brassell/King, Banking on IP? The role of intellectual property and intangible assets in facilitating business finance; Terroir, Rebalancing the Patent Economy, p. 71.
- [25] OECD, New Sources of Growth: Knowledge-based Capital, p. 58.
- [26] Id., p. 12
- [27] WHO, WIPO, WTO, Promoting Access to Medical Technologies and Innovation, p. 105.
- [28] OECD, New Sources of Growth: Knowledge-based Capital, p. 12.
- [29] WIPO document WIPO/GC/IP/GE/16/1, p. 25; 5 % of the 2015 Model List; however, a rising trend due to the fact that the WHO start to consider more innovative treatments essential; Beall/Attaran, Global Challenges Report: Patent-based analysis of the World Health Organization's 2013 Model List of Essential Medicines, 5% earlier.
- [30] Aitken et al., Understanding the pharmaceutical value chain, p. 21f.
- [31] Cockburn/Lanjouw/Schankerman, Global diffusion of new drugs: The role of patent policy, price controls and institutions, p. 16f.; Lanjouw, Patents, Price Controls and Access to New Drugs: How policy affects global market entry, 41f.
- [32] Maskus, Intellectual Property Rights and Social Development: Issues and Evidence, WIPO/IPDA/ GE/16/T4.
- [33] Borrell, Patents and the faster introduction of new drugs in developing countries. Applied Economics Letters, 12(2), 379f.
- [34] Kyle, Margaret, Intellectual Property Rights, Price, and Access to Innovation: Evidence from

the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), WIPO/IP/ECON/GE/3/13/INF.1.

[35] Kyle/Qian, Intellectual Property Rights and Access to Innovation: Evidence from TRIPS, p. 2f.

[36] Chaudhuri et al., Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India, p. 35f.

[37] Duggan et al., The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India, p. 103f.

[38] Alazarki, The 10 Biggest-Selling Drugs That Are About to Lose Their Patent, Daily Finance, 27 February 2011.

[39] F. Angeli, With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS, I: Health Policy and Planning 2014; 29: 280–291, p. 283.

[40] OECD, New Sources of Growth: Knowledge-based Capital, ENQUIRIES INTO INTELLECTUAL PROPERTY'S ECONOMIC IMPACT, Chapter 1, p. 33, calculations based on PATSTAT (EPO, April 2012), October 2012.

